US › Healthcare

Equillium Inc (EQ)

US · Healthcare · Biotechnology

$1.19-9.85%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.7M

EPS

$-0.04

EPS estimate

$-0.05

EPS came in at -0.04 against a street estimate of -0.05 — a beat of 20.0%.

Key statistics

Market cap

$89.4M

Forward P/E

1.5

P/B

2.18

Book value

$0.88

EPS (TTM)

$-0.14

52-week high

$3.54

52-week low

$0.76

50-day MA

$2.05

200-day MA

$2.08

Beta

1.92

Analyst view

Analysts rate Equillium Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $8.56.

Shareholding

Insiders

16.00%

Institutions

65.76%

Largest institutional holders

Fund	Stake
HHG PLC	10.24%
Jupiter Topco LLC	10.24%
Decheng Capital LLC	7.01%
Affinity Asset Advisors, LLC	6.47%
ADAR1 Capital Management LLC	5.93%
Aberdeen Group PLC	5.73%
Woodline Partners LP	5.52%
RA Capital Management, LLC	4.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Equillium Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.